

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 3

April 13, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Horowitz Bruce
 (Last) (First) (Middle)

7327 OAK RIDGE HIGHWAY, Â SUITE A

(Street)

KNOXVILLE, Â TN Â 37931

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
 04/03/2017

3. Issuer Name and Ticker or Trading Symbol

PROVECTUS BIOPHARMACEUTICALS, INC.
 [PVCT]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,392,243	D	Â
Common Stock	50,000	I	By spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	------------------------------------	---------------------------------	---

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Common Stock Warrants (right to buy)	Â (1)	10/23/2018	Common Stock	100,000	\$ 1	D	Â
Common Stock Warrants (right to buy)	Â (1)	12/31/2018	Common Stock	100,000	\$ 2	D	Â
Common Stock Warrants (right to buy)	Â (1)	12/31/2018	Common Stock	400,000	\$ 1	D	Â
Common Stock Warrants (right to buy)	Â (1)	06/19/2020	Common Stock	400,000	\$ 0.85	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Horowitz Bruce 7327 OAK RIDGE HIGHWAY, SUITE A KNOXVILLE, TN 37931	Â X	Â	Â	Â

Signatures

/s/ Bruce Horowitz 04/13/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The common stock warrants are exercisable currently.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.